Lombardy Section Italian Society Infectious And Tropical Diseases -
Infez Med. 2020;28(2):143-152.
The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this «vademecum» with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.
新型冠状病毒肺炎疫情在意大利蔓延，尤其是在伦巴第大区，这决定了有必要规范治疗方法，以便为伦巴第大区的所有医院提供相同的治疗指征。然而，此前尚无专门批准用于治疗新型冠状病毒肺炎的药物。意大利传染病和热带病学会伦巴第分会编写了这份“手册”，旨在探究目前有关可能有效治疗新型冠状病毒肺炎的药物的证据。此外，还成立了一个包括重症监护专家在内的多学科小组，以提供有关支持措施和类固醇使用的指征。为了根据呼吸状况的严重程度对患者进行分层，提出了一种新的分级量表。最后，组建了一个由免疫学家和风湿病学家组成的合作小组，目的是就托珠单抗的使用提供一些指导，托珠单抗是治疗大多数新型冠状病毒肺炎患者出现的高炎症状态的一种有前景的选择。
